Futura Medical has reported that the designated EU Notified Body has completed its review of MED3000’s Technical Dossier and recommends its certification as a Class 2b approved medical device. The certificate is expected to be issued before the end of May, which is ahead of the timings we had expected (we had estimated mid-2021 in our modelling). This makes MED3000, a proprietary topical gel for erectile dysfunction (ED), the first clinically proven OTC treatment that is approved across Europe.
19 Mar 2021
EU Notified Body recommends MED3000 approval
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
EU Notified Body recommends MED3000 approval
Futura Medical plc (FUM:LON) | 35.4 0.1 0.7% | Mkt Cap: 106.9m
- Published:
19 Mar 2021 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
2
Futura Medical has reported that the designated EU Notified Body has completed its review of MED3000’s Technical Dossier and recommends its certification as a Class 2b approved medical device. The certificate is expected to be issued before the end of May, which is ahead of the timings we had expected (we had estimated mid-2021 in our modelling). This makes MED3000, a proprietary topical gel for erectile dysfunction (ED), the first clinically proven OTC treatment that is approved across Europe.